Cargando…

Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?

The treatment of obesity can no longer be reduced to a simplistic view of weight loss. Metabolic adaptation leads to systematic weight regain following weight-loss efforts, and new obesity treatments should therefore aim to induce long-standing double-digit weight loss, and thus improve and even rev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colin, Ides M, Gérard, Katherine M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Touch Medical Media 2022
Materias:	Diabetes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354513/ https://www.ncbi.nlm.nih.gov/pubmed/35949360 http://dx.doi.org/10.17925/EE.2022.18.1.35

Ejemplares similares

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
por: Sandhu, Hera, et al.
Publicado: (2023)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
por: Wharton, Sean, et al.
Publicado: (2021)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
por: Friedrichsen, Martin, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
por: Alabduljabbar, Khaled, et al.
Publicado: (2022)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
por: Perreault, Leigh, et al.
Publicado: (2022)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
por: Blundell, John, et al.
Publicado: (2017)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis
por: Kanters, Steve, et al.
Publicado: (2019)

Game Changers
Publicado: (2014)

Game Changers
Publicado: (2014)

Game Changers
Publicado: (2015)

Game Changers
Publicado: (2015)

Game changers
Publicado: (2016)

Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India
por: RoyChaudhuri, Soumyabrata, et al.
Publicado: (2023)

Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis
por: Smith, Inger, et al.
Publicado: (2022)

Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease
por: Colin, Ides M, et al.
Publicado: (2023)

A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide
por: Tham, Lai San, et al.
Publicado: (2021)

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
por: Capehorn, Matthew, et al.
Publicado: (2021)

Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
por: Stafford, Sara, et al.
Publicado: (2022)

Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
por: Stafford, Sara, et al.
Publicado: (2022)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
por: Evans, Marc, et al.
Publicado: (2023)

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management
por: Enebo, Lone B, et al.
Publicado: (2021)

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
por: Kushner, Robert F., et al.
Publicado: (2020)

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials
por: Verma, Subodh, et al.
Publicado: (2022)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

SDF − a game changer?
por: Remtulla, A.
Publicado: (2020)

LEAP2: Next game-changer of pharmacotherapy for overweight and obesity?
por: Liu, Dan, et al.
Publicado: (2022)

Metabolic Phenotypes—The Game Changer in Quality of Life of Obese Patients?
por: Mitu, Ivona, et al.
Publicado: (2022)

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
por: Carlsson Petri, Kristin Cecilie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_51qrecu9dfg6vpra66442m6loq